Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

CD9-enriched extracellular vesicles from chemically reprogrammed basal progenitors of salivary glands mitigate salivary gland fibrosis

Park S., Yoon YJ., Hong Y., Yu J., Cho JM., Jeong YJ.

Animal Study on Hip, published in Bioact Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2025)
Reported sample size
—
Source database
Europe PMC
PMID
39925710
PMCID
PMC11803853
DOI
10.1016/j.bioactmat.2025.01.019
Citations
3

Abstract (original English)

Extracellular vesicles (EVs) derived from stem cells offer promising potential for cell-free therapy. However, refining their cargo for precise disease targeting and delivery remains challenging. This study employed chemical reprogramming via dual inhibition of transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) to expand salivary gland basal progenitor cells (sgBPCs). CD9-enriched (CD9 + ) EVs were then isolated from the sgBPC secretome concentrate using a dual microfluidic chip. Notably, CD9 + EVs demonstrated superior uptake by salivary epithelial cells compared to CD9-depleted (CD9 - ) EVs and total EVs. In vivo studies using a salivary gland (SG) obstruction mouse model and ex vivo studies in SG fibrosis organoids revealed that CD9 + EVs significantly enhanced anti-fibrotic effects over CD9 - EVs and control treatments. The presence of miR-3162 and miR-1290 in CD9 + EVs supported their anti-fibrotic properties by downregulating ACVR1 expression. The chemical reprogramming culture method effectively expanded sgBPCs, enabling consistent and scalable EV production. Utilizing microfluidic chip-isolated CD9 + EVs and ductal delivery presents a targeted and efficient approach for anti-fibrotic SG regeneration.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research